Novo Holdings co-leads $120 million Series E Financing of Supira Medical to Advance Percutaneous Ventricular Assist Device Technology

Breakthrough technology targets high-risk coronary intervention and cardiogenic shock treatments

COPENHAGEN & LOS GATOS, CA., March 27, 2025 – Novo Holdings, a leading life science investor today announced that it has co-led a $120 million Series E financing of Supira Medical, Inc. (Supira), a clinical-stage Shifamed portfolio company. Led by Novo Holdings alongside the Qatar Investment Authority, the financing round also includes two undisclosed strategic investors and participation from Supira’s existing investors including Cormorant Asset Management and The Capital Partnership (TCP), 415 CAPITAL, AMED Ventures, PA MedTech VC fund, and Unorthodox Ventures. Funds will be used to expand Supira’s clinical programs for both high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS). This clinical expansion includes the SUPPORT II U.S. Pivotal Study for HRPCI, which will be used to seek FDA PMA approval.

As a leading life sciences investor, Novo Holdings continues to drive forward breakthrough medical technologies that address critical unmet clinical needs. This investment in Supira Medical exemplifies the firm's strategic approach to supporting early-stage companies developing potentially transformative therapies in high-impact medical domains like cardiovascular intervention. As part of this strategic investment, Novo Holdings U.S. Partner Dr. Christopher Shen will join Supira Medical's Board of Directors.

Dr. Christopher Shen, Partner, Novo Holdings U.S. said: “We believe there is a massive unmet need for next generation ventricular support devices to promote myocardial recovery and improve peripheral organ perfusion in HRPCI and CS patients. The Supira team has built a strong clinical foundation to further validate their advanced low-profile, high flow technology platform in two important segments of interventional heart failure, and we are pleased with their excellent progress bringing this therapy closer to market.”

Dr. Nitin Salunke, President and CEO of Supira Medical added: “We are grateful for the continued confidence and support from our current investors and delighted to welcome new world-class investors to this financing consortium. This significant capital raise underscores the team’s tremendous progress as we look forward to exciting opportunities ahead of us to improve clinical outcomes for both HRPCI and cardiogenic shock patients.”

The company recently completed enrollment of its U.S. SUPPORT I Early Feasibility Study (EFS), enrolling a total of 15 patients across four clinical sites. The prospective, single-arm clinical study evaluated the safety and feasibility of Supira’s innovative pVAD in patients undergoing HRPCI.

pVADs are important for supporting cardiovascular function during HRPCI, particularly in patients with complex coronary anatomy, compromised hemodynamics, and multiple comorbidities. They are also used in cardiogenic shock, a high-mortality condition where the heart is too weak to pump sufficient blood to vital organs, usually resulting from a heart attack or heart failure. The Supira System is an investigational device and is not approved for sale in the U.S. or anywhere in the world.

About Supira Medical, Inc.

Supira Medical, a clinical-stage Shifamed portfolio company, is focused on the development of a next-generation pVAD for use in high-risk patients undergoing interventional procedures and experiencing cardiogenic shock. To date, the Supira System has benefitted 85 HRPCI patients. To learn more about Supira Medical, please visit www.supiramedical.com. 

About Qatar Investment Authority 

QIA is the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term perspective that can deliver sustainable returns and contribute to the prosperity of the State of Qatar. Learn more at http://www.qia.qa.

About Shifamed, LLC. 

Founded by serial entrepreneur Amr Salahieh, Shifamed is a highly specialized medical innovation hub focused on developing solutions that accelerate time to market, reduce risk, increase impact, and forge a path toward a world where patients are able to live longer, healthier lives. To learn more about Shifamed, please visit www.shifamed.com.